Adrenaline autoinjector cost utility analysis

OIA response

Request dated 26 March 2019 for information relating to adrenaline autoinjectors.

[Name and email address redacted]

15 April 2019

Dear [Name redacted]


Thank you for your request dated 26 March 2019 under the Official Information Act 1982 (OIA) for information relating to adrenaline autoinjectors. You asked for any cost utility analyses performed by PHARMAC in relation to adrenaline autoinjectors (such as EpiPen) for the treatment of anaphylaxis, from 2004 onward. 

The requested documents are attached [PDF, 698 KB].

Please note that PHARMAC approaches its assessment of requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party).  We have redacted a small amount of information from the documents as we consider this is necessary to:

  • protect the privacy of natural persons (section 9(2)(a));
  • protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
  • protect information which is subject to an obligation of confidence or which any person has been or could be compelled to provide under the authority of any enactment, where the making available of the information would be likely to prejudice the supply of similar information, or information from the same source, and it is in the public interest that such information should continue to be supplied (section 9(2)(ba)(i));
  • enable PHARMAC to carry out, without prejudice or disadvantage, commercial activities (section 9(2)(i)); and
  • enable PHARMAC to carry on, without prejudice or disadvantage, negotiations, including commercial negotiations (section 9(2)(j));

As required under the OIA, we have also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available.  In this case we did not consider that the public interest outweighed the reasons for withholding the information. 

We trust that the provision of these documents answers your queries, if you have any further questions please feel free to contact us again.

Yours sincerely

[Alison Hill's signature]

Alison Hill
Director, Engagement and Implementation